Adults with metastatic prostate cancer invited to be in a combination chemotherapy/hormone therapy study

IRB/UVA Tracking #
Principal Investigator
Robert Dreicer
Julio Torres III
Contact Phone
Official Trial Title
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have metastatic prostate cancer. The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone based therapy abiraterone acetate (also known as Zytiga®) in combination with prednisone. In this research study, you will get either the standard of care combination of abiraterone acetate and prednisone, or you will get abiraterone acetate and prednisone in combination with the chemotherapy drug cabazitaxel.

Your participation will continue as long as the treatment is helping you. Treatment with abiraterone and prednisone will continue until you or your doctor decide it is no longer good for you to do so. The treatment with cabazitaxel will stop after a maximum of 126 days. There will also be a follow up period lasting 5 years.

Study-related procedures that are being done beyond your standard of care will be provided at no
cost to you or your insurance.

Additional information can be found here: